In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on CymaBay Therapeutics (CBAY), with a price target of $23. The company’s shares closed yesterday at $10.29.
“We remind investors that the rationale in NASH of seladelpar, a once daily oral PPAR δ agonist, is based on the broad cardiovascular, metabolic and anti-inflammatory activity of the drug seen in a prior Phase 2 mixed dyslipidemia study, as well as on substantial improvements in ballooning, transaminases, glycemic control and fibrosis in the foz/ foz mouse model of NASH. Affirm Buy.”
According to TipRanks.com, Arce is a 4-star analyst with an average return of 8.1% and a 38.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Currently, the analyst consensus on CymaBay Therapeutics is a Strong Buy with an average price target of $17.80, a 73.0% upside from current levels. In a report issued on February 11, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $20 price target.
See today’s analyst top recommended stocks >>
Based on CymaBay Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $18.56 million. In comparison, last year the company had a GAAP net loss of $5.04 million.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Carl Goldfischer, a Director at CBAY sold 11,675 shares for a total of $105,309.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of biopharmaceutical products. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid.